IACS-8779 

IACS-8779 is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy^[1].

Mice are implanted bilaterally with B16-Ova, and IACS-8779 (compound 1a) is administered at 10 μg dose with three intra-tumoral injections, on one flank only, on day 6, 9, 12 post implantation. While IACS-8779 shows comparable antitumor activity on the injected flank, IACS-8779 achieves superior regression on the untreated tumor in the contralateral flank, suggesting a more significant systemic immune response compared to the benchmark analogs. Treatment with IACS-8779 also results in a higher number of mice cured of both tumors compared to benchmarks^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

689.56

C₂₁H₂₅N₉O₁₀P₂S₂

2243079-26-5

NC1=C(C2=NC=N1)N=CN2[C@@H]3O[C@H]4[C@H]([C@H]3O[P@](S)(OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C7=C(C=C6)C(N)=NC=N7)O)O[P@](S)(OC4)=O)=O)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ager CR, et al. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. Bioorg Med Chem Lett. 2019 Oct 15;29(20):126640.  [Content Brief]